Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis-Reference-Cited by-同舟云学术

Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis

Published:2018-01-23 Issue:6 Volume:24 Page:813-815
ISSN:1352-4585
Container-title:Multiple Sclerosis Journal
language:en
Short-container-title:Mult Scler

Author:

di Ioia Maria¹,Farina Deborah¹,di Tommaso Valeria¹,Travaglini Daniela²,Pietrolongo Erika¹,Onofrj Marco¹,de Luca Giovanna²

Affiliation:

1. MS Center, Neurologic Clinic, SS. Annunziata Hospital, Chieti, Italy/Department of Neuroscience, Imaging and Clinical Sciences, “G. d’Annunzio” University, Chieti, Italy

2. MS Center, Neurologic Clinic, SS. Annunziata Hospital, Chieti, Italy

Abstract

Background: Alemtuzumab, approved for multiple sclerosis (MS), can cause secondary autoimmune adverse events including thyroid disorders, immune thrombocytopenia (ITP), and glomerular nephropathies. Non-ITP autoimmune cytopenias are rarely reported. Objective: To report a case of autoimmune hemolytic anemia (AIHA) and nephropathy in a MS patient treated with alemtuzumab. Case report: A 34-year-old man with MS developed albuminuria and AIHA after the first and only alemtuzumab treatment, with positive Coombs’ direct and indirect tests and IgG autoantibodies. Both AIHA and nephropathy resolved 1 month after treatment with steroids and intravenous immunoglobulins. Conclusion: Our report adds to literature on AIHA and nephropathy after alemtuzumab treatment and suggests to add Coombs’ tests to the screening panel required for alemtuzumab treatment.

Publisher

SAGE Publications

Subject

Clinical Neurology,Neurology

Link

http://journals.sagepub.com/doi/pdf/10.1177/1352458517743093

Reference8 articles.

1. Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use

2. Mode of action and clinical studies with alemtuzumab

3. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial

4. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Disease-modifying therapies and hematological disorders: a systematic review of case reports and case series;Frontiers in Neurology;2024-06-18

2. RETRACTED: An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis;Pharmaceutics;2023-05-22

3. Severe Autoimmune intravascular hemolytic anemia in patients receiving Alemtuzumab for Multiple sclerosis;Blood Advances;2022-11-14

4. Alemtuzumab-induced red cell aplasia and other immune cytopenias: not so ‘pure’;Immunotherapy;2022-02

5. Skin Autoimmunity Secondary to Alemtuzumab in a Tertiary Care Spanish Hospital;Neurology: Clinical Practice;2021-07-16